What are the limitations of the imwg response?

While the imwg response is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the imwg response to ensure safe bedside use and optimal diagnostic accuracy.

How does the imwg response compare to other Hematology scores?

The imwg response is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the imwg response free to use?

Yes. OpiCalc provides the imwg response completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

OpiCalc

935 Clinical Tools

OpiCalc

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

IMWG Response Criteria (Myeloma)

IMWG Myeloma Response: Standardized assessment for Myeloma therapy. Use clinical data and marrow results to determine remission depth.

Myeloma Response Status

None

Criteria for PR or better not yet met based on selected factors.

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Defining the depth of response in patients undergoing therapy for Multiple Myeloma.

Standardizing results for clinical trials using M-protein and Free Light Chain (FLC) metrics.

Differentiating Very Good Partial Response (VGPR) from Complete Response (CR).

Patient Population

Patients with a diagnosis of Multiple Myeloma according to IMWG criteria.

Section 2

Formula & Logic

Response Categories

Category	Definition
sCR (Stringent CR)	CR criteria PLUS normal FLC ratio and absence of clonal cells in marrow by IHC/flow.
CR (Complete)	Negative Serum/Urine IFE, disappearance of plasmacytomas, and ≤ 5% marrow plasma cells.
VGPR	≥ 90% reduction in serum M-protein OR urine M-protein < 100 mg/24h.
PR (Partial)	≥ 50% reduction in serum M-protein and ≥ 90% reduction in urine M-protein (or < 200 mg/24h).
MR (Minimal)	25–49% reduction in serum M-protein.

Section 3

Pearls/Pitfalls

The FLC Ratio

The Free Light Chain (FLC) ratio is critical for "Stringent CR" (sCR). A patient might have negative immunofixation but still have an abnormal ratio, which excludes sCR.

Marrow Requirement

To confirm CR, a marrow biopsy must show ≤ 5% plasma cells. A patient with negative IFE but 10% marrow cells is technically in PR/VGPR, not CR.

Section 4

Evidence Appraisal

Primary Consensus

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Kumar S et al. • Lancet Oncology. 2016;17(8):e328-e346.

View Source

Section 5

Literature

Development

Evolved from the original EBMT criteria (1998) to incorporate modern sensitive assays like the Freelite assay (FLC) and multiparametric flow cytometry.

Last Comprehensive Review: 2026

Related Hematology Tools

aaIPI

IPSID / Lugano Classification

Deauville Score Interpreter

CLL-IPI

Binet / Rai Staging

iwCLL Response Criteria

Revised Response Criteria

PCNSL MSKCC Score

ISS

R-ISS

Have feedback about this calculator?Let us know.